VSELs might be an ideal cell therapy to regenerate the body's immune system and repair other tissues damaged by radiation exposure
NBS has been awarded the 2nd year of a 2 year grant totaling $595,252 for the Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) Stem Cells as a Countermeasure to Radiation Threat, Grant Number 5R43AI098325-02 from the NIAID, a division of the NIH.
The Bottom Line: This award funds studies to investigate the potential of very small embryonic-like stem cells as a countermeasure to radiological and nuclear threat. The award included $295,252 for the first year and $300,000 for the second year of the project. NBS expects to file an IND with the FDA in late 2013 or early 2014 to initiate a NIH funded human clinical study treating periodontitis with VSELs.
NBS closed at $0.69 with solid volume of 1.127 M shares as futures hold gains with a trading expectation +$0.01 to +$0.02 to drive the shares above $0.70. NBS is one company that has … GOOD news in the last few days.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.